Opinion of the President – Embolisation of intracranial aneurysms with an intracranial aneurysm embolisation device (flow disruptor)
On 30 November 2022 the President of the Agency for Health Technology Assessment and Tariff System issued the following recommendation:
Recommendation No. 111/2022 of 30 November 2022. of the President of the Agency for Health Technology Assessment and Tariff System on the appropriateness of qualifying a healthcare benefit: “Embolisation of intracranial aneurysms with an intracranial aneurysm embolisation device (flow disruptor)” as a guaranteed hospital treatment healthcare service.